US2019192635A1PendingUtilityA1

Combination of an insulin and a glp-1-agonist

61
Assignee: SANOFI AVENTIS DEUTSCHLANDPriority: Oct 17, 2008Filed: Oct 19, 2018Published: Jun 27, 2019
Est. expiryOct 17, 2028(~2.2 yrs left)· nominal 20-yr term from priority
Inventors:Ulrich WernerBarbel Rotthauser
A61P 43/00A61P 5/00A61P 5/48A61P 5/50A61P 3/10A61P 3/08A61P 3/04A61P 1/18A61K 38/26A61K 38/28A61K 2300/00A61K 38/16A61K 38/17
61
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist.

Claims

exact text as granted — not AI-modified
1 : An injectable device comprising a pharmaceutical formulation, wherein the pharmaceutical formulation comprises a combination of:
 (1) a GLP-1 receptor agonist, and   (2) an insulin;   wherein the device is capable of selecting the dosage of the GLP-1 receptor agonist independently of the dosage of the insulin, and   wherein the device is capable of administering a combination of the selected dosage of the GLP-1 receptor agonist and the selected dosage of the insulin in essentially the same volume as the selected dosage of the insulin alone.   
     
     
         2 : The device of  claim 1 , wherein the GLP-1 receptor agonist is GLP-1, exendin-3, exendin-4, or a derivative thereof. 
     
     
         3 : The device of  claim 1 , wherein the GLP-1 receptor agonist is desPro 36 exendin-4(1-39)-Lys 6 -NH 2  (AVE0010). 
     
     
         4 : The device of  claim 1 , wherein the GLP-1 receptor agonist is Arg34,Lys26(Nε(γ-glutamyl(Nα-hexadecanoyl)))GLP-1(7-37) (liraglutide). 
     
     
         5 : The device of  claim 1 , wherein the insulin is an insulin derivative. 
     
     
         6 : The device of  claim 1 , wherein the insulin is an insulin analog. 
     
     
         7 : The device of  claim 1 , wherein the insulin is insulin aspart, insulin lispro, or insulin detemir. 
     
     
         8 : The device of  claim 1 , wherein the insulin is insulin glargine. 
     
     
         9 : The device of  claim 1 , wherein the concentration of insulin is about 40-500 units/mL. 
     
     
         10 : The device of  claim 1 , wherein the concentration of GLP-1 receptor agonist is about 40-500 units/mL. 
     
     
         11 : The device of  claim 1 , wherein the insulin is administered at a dosage of 5 to 100 U. 
     
     
         12 : The device of  claim 1 , wherein the GLP-1 receptor agonist is administered at a dosage of 5 μg to 2 mg.

Join the waitlist — get patent alerts

Track US2019192635A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.